Newco
-
External Collaboration: The Core Engine Behind AbbVie’s Decade-Long Explosive Growth
DrugTimes BD Team has contributed to successful deals with a total value of US$2.3B
-
Amgen’s BD Model: A Benchmark for Cross-Border Biotech Collaboration
DrugTimes BD Team has contributed to successful deals with a total value of US$2.3B
-
27 Assets for Licensing【DrugTimes BD Project】
If you are interested in these opportunities, please feel free to contact DrugTimes BD Team (Email: BD@drugtimes.cn)
-
恒瑞Newco公司获6亿美元B轮融资！
药时代寻找对创新药Biotech 实实在在感兴趣且资金充沛的投资公司 请立即联系药时代BD团队（BD@drugtimes.cn）！ 正文共：800字 预计阅读时间：2分钟 202…
-
超10亿美元！迈威生物NewCo出海
某公司ADC资产（技术+产品）剥离，寻找有实力的合作伙伴，合作模式灵活可谈！ 请感兴趣的公司立即联系药时代BD团队（BD@drugtimes.cn）！ 正文共：700字 预计…
-
刚刚！超10亿美元！恒瑞医药宣布Myosin抑制剂NewCo出海
融资的机会来了！~ 多家知名VC公司寻找优质投资标的， 感兴趣的管线包括： （1）针对实体瘤的创新性TCE、（2）新靶点/新核素的创新性核药、（3）Abeta双靶点等CNS创新…
-
The Three Fates of Newco and the Birth of LIDNewco
LIDNewCo=License In-Development-NewCo model, is the 2.0 version of NewCo
-
进军全球最大的美国市场？美国本土团队助您一臂之力！
欢迎联系药时代！我们的联系邮箱是：consulting@drugtimes.cn
-
>$600M! Aditum Bio and Leads Biolabs Announce the Formation of Oblenio Bio to Develop a Tri-Specific T-Cell Engager for Autoimmune Disorders
Congratulations! This is the latest successful case of NewCo for China pharma and biotech companies
-
超6亿美元！维立志博与Aditum Bio合作成立Oblenio Bio，全力推进自免领域三特异性T细胞衔接器研发
热烈祝贺！NewCo模式的最新成功案例
